新闻
CMS: Approval Of Drug Clinical Trials For Complement-Mediated Kidney Disease Indication Of Innovative Drug Complement Factor B Inhibitor CMS-D017.
04 Feb 2026 10:21China Medical System Holdings Limited is pleased to announce that innovative drug CMS-D017 capsules self-developed by the Group, has obtained the Drug Clinical Trial Approval Notice issued by National Medical Products Administration on 3 February 2026...
Attachments:
Source: ShareInvestor Express
